ANAB Insider Activity: Option Exercise, ESPP Purchase and 10b5-1 Sale Reported
Rhea-AI Filing Summary
Eric J. Loumeau, Chief Legal Officer of AnaptysBio, Inc. (ANAB), reported both purchases and sales of company common stock on 09/30/2025. He acquired 5,000 shares by exercising employee stock options at an exercise price of $14.02 and an additional 1,325 shares under the company ESPP included in the reported holdings, bringing his post-transaction direct ownership to 17,328 shares. He also sold 8,240 shares at $29.00 per share under a 10b5-1 trading plan adopted April 11, 2025.
The Form 4 shows he retains outstanding options to purchase 68,000 shares exercisable under the option described and additional unvested options aggregating up to 422,310 shares that vest per their terms. Transactions were routine insider activity documented under Section 16 reporting rules.
Positive
- Exercise of options converted compensation into 5,000 common shares at a $14.02 exercise price
- ESPP participation added 1,325 shares to the reporting person's holdings
- Sale executed under 10b5-1 plan, indicating a pre-established trading plan that provides compliance clarity
Negative
- Sale of 8,240 shares reduced direct holdings from the pre-transaction level to 9,088 shares before accounting for acquisitions
- Significant unexercised option pool disclosed (68,000 exercisable plus up to 422,310 additional options), representing potential future dilution
Insights
TL;DR: Routine insider option exercise combined with a planned sale under a 10b5-1 plan; net effect modest given total outstanding options.
The reporting shows a simultaneous exercise of options and an ESPP acquisition totaling 6,325 shares and a sale of 8,240 shares executed under a pre-established 10b5-1 plan. The exercise price of $14.02 versus the sale price of $29.00 indicates the sale likely occurred at a profit relative to the exercised lots. The filing discloses materially larger unexercised option holdings (68,000 listed plus up to 422,310 additional options) which could affect future dilution but are disclosed with vesting schedules as required.
TL;DR: Disclosure follows standard Section 16 requirements; sale executed under a 10b5-1 plan reduces regulatory scrutiny.
The Form 4 documents compliant reporting of insider transactions, including exercise/vest schedules and identification of the 10b5-1 plan that governed the sale. The filing clarifies direct ownership and nature of indirect holdings and includes ESPP participation. No unexplained transfers or unusual forms of disposition are present in the record provided.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) | 5,000 | $0.00 | -- |
| Exercise | Common Stock | 5,000 | $14.02 | $70K |
| Sale | Common Stock | 8,240 | $29.00 | $239K |
Footnotes (1)
- Includes the acquisition of 1,325 shares acquired under the Company's ESPP. The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025. The stock option vested and is exercisable as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. In addition to the remaining options to purchase 68,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 422,310 shares of common stock, which options vest according to their terms.
FAQ
What insider transactions did ANAB Chief Legal Officer Eric Loumeau report on 09/30/2025?
Were any sales executed under a trading plan for ANAB insider transactions?
What exercise price and sale price are reported in the Form 4 for ANAB transactions?
Does the filing indicate whether the transactions were direct or indirect?
